Skip to content

iBio Reports Triple Milestone

Positive pre-clinical in vivo data for three immuno-oncology candidates

Read More

AI-Powered Precision Antibody Therapeutics

Epitope-Steering and Antibody Optimization for Accelerating Cancer Immunotherapies

About Us

Discovery Platform

FROM PRECISION ANTIBODY IDENTIFICATION AND OPTIMIZATION TO TAILORED BI-SPECIFICS

Platform

Therapeutic Pipeline

RAPIDLY ADVANCING HARD-TO-ENGINEER ANTIBODIES

Explore

Partner with iBio

License our discovery platform or collaborate with us to advance our high-value pipeline assets

Contact Us

Announcing
EngageTX™

a CD3-BASED T-CELL ENGAGER PANEL FOR
OPTIMIZING BI-SPECIFICS

Read More

Discovery Platform

A Powerful Tech Stack for Validating Difficult Targets

Discover More

Therapeutic Candidates

Learn how we are deploying our AI Drug Discovery Platform to develop a robust immuno-oncology pipeline

Learn More

The Expertise Behind the AI

Meet the team driving iBio’s powerful tech stack for drug discovery

Matt Greving, Ph.D.

Vice President, Platform Technology and Machine Learning 

Alex Taguchi, Ph.D.

Director, Machine Learning Research & Development

Cody Moore

Senior Platform Manager
Meet the Leadership Team

Latest News and Updates

Press Releases

See iBio's latest press releases
Recent Announcements

iBio in the News

Learn about iBio’s newest collaborations, data announcements, and more
Read More

Join us at Discovery on Target, September 25th-28th

Alex Taguchi, PhD, Director, Machine Learning, Antibody Discovery presents
Learn More

Corporate Presentation

Get the most up-to-date company information quarterly
View Here

Accelerating Drug Discovery Through AI and Machine Learning

For Investor inquiries, please visit our Investor Site

Visit Here
Top